Spyre Therapeutics, Inc. SYRE Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept syre:AcquiredInProcessResearchAndDevelopment.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s acquired in-process research and development?
- Spyre Therapeutics, Inc. (SYRE) reported acquired in-process research and development of $0 in Q1 2026.
- What does acquired in-process research and development mean?
- This represents the value assigned to research and development projects acquired through business combinations that have not yet reached technological feasibility. It is often expensed immediately upon acquisition, impacting net income without a corresponding cash outflow in the operating section if treated as a non-cash adjustment. It highlights the company's strategy for inorganic growth in its pipeline.